卡博桑提尼布-脂复合物用于增强溶解性,生物可用性和减少肝癌中毒性的肝癌
Jayesh Patil1, Sankha Bhattacharya1, Suprit D Saoji2
1Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, India.
Therapeutic delivery
|November 29, 2024
概括
一种新的卡博赞提尼布-脂复合物 (CBZ-PLS) 配方显著提高了溶解性和生物可用性. 这种增强复合体显示出对肝癌细胞的治疗疗效有所提高.
科学领域:
- 药理学和药物输送 药理学和药物输送
- 生物化学 生物化学
- 在瘤学瘤学.
背景情况:
- 卡博桑提尼布 (CBZ) 是一种氨酸激酶抑制剂,具有治疗潜力,但具有较差的水溶性,低生物可用性和高毒性.
- 这些局限性阻碍了其临床应用,需要制定改善其药理动力学和药理动力学特征的策略.
研究的目的:
- 开发和描述一个卡博桑提尼布-脂复合物 (CBZ-PLS),以增强卡博桑提尼布的治疗潜力.
- 评估CBZ-PLS与自由卡博赞提尼布相比提高的溶解性,生物可用性,体外释放,细胞毒性和稳定性.
主要方法:
- 卡博桑提尼布-脂复合物 (CBZ-PLS) 是使用溶剂蒸发技术来制备的,该技术是通过Box-Behnken设计进行优化.
- 描述涉及确认分子相互作用的技术,评估包括溶解性,体外释放动力学,Wistar大鼠的药理动力学,以及对HepG2细胞系的细胞毒性测定.
主要成果:
- 通过CBZ-PLS,可溶性增加了126倍,并增强了体外药物释放.
- 药理动力学研究显示,生物可用性增加了1.58倍,在6个月内确认了生物相容性和稳定性.
- 在HepG2细胞中,CBZ-PLS表现出优异的细胞毒性,诱导细胞亡,抑制迁移,增加ROS生成和DNA碎片化.
结论:
- 卡博桑提尼布-脂复合物 (CBZ-PLS) 显著提高了卡博桑提尼布的可溶性,生物可用性和治疗疗效.
- CBZ-PLS代表了改善肝癌治疗的有希望的策略,提供了一种更有效的治疗方法.
更多相关视频
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH
1.1K
Drug absorption within the gastrointestinal (GI) tract is a complex process influenced by several critical factors, including the site pH, the drug's dissociation constant (pKa), and the drug's lipophilicity. The GI tract exhibits a pH gradient, with an acidic environment in the stomach and a more alkaline environment in the small intestine. This pH variation directly affects the ionization state of drugs.
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
1.1K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Factors Influencing Bioavailability: First-Pass Elimination
6.1K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
6.1K
Drug Distribution: Tissue Binding
2.6K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.6K


